Tag Archives: Alzheimer’s

Anavex Life Sciences Corp (NASDAQ:AVXL), the clinical stage biopharmaceutical developing treatments for neurodegenerative and neurodevelopmental diseases, has been recently under the radar of many institutional investors. We assessed the company...

While the shorts continue their in-vein efforts to beat down on Anavex Life Sciences Corp. (NASDAQ:AVXL), the company continues to hold it’s own in the markets. At last count, Anavex traded for a little over $5.82 (pre market on Tuesday),...

Neurotrope Inc (NASDAQ:NTRP) just put out its hotly anticipated phase II Alzheimer’s data and as we might have predicted, the shorts are out in force. Markets are jumping on the downside bandwagon, and Neurotrope is heading into the open...

Here at Insider Financial, we work hard to uncover potential movers ahead of the wider markets. In the biotech space, there are plenty of these sorts of opportunities, but there’s so much noise in the sector that separating the wheat...

Back in December 2016, we looked at Neurotrope Inc (OTCMKTS:NTRP) as part of this coverage. We noted that the company had just taken a hit on the announcing of a private placement, and that (as we see so often in biotech) the market response...

While the majority of our competitors have warned investors away from Anavex Life Sciences Corp. (NASDAQ:AVXL) over the last six months, here at Insider Financial we have repeatedly highlighted the company as having the potential to offer investors...

Anavex Life Sciences Corp. (NASDAQ:AVXL) is picking up strength on the back of a corporate update, which offered a high degree of clarity in to the company’s numbers and operations ahead of what looks set to be a pivotal 2017 for the...

One of our most closely watched biotechs is Anavex Life Sciences Corp. (NASDAQ:AVXL). The company is a development stage biotech working to bring an alternative form of the current in-development Alzheimer’s treatments to market. It has...

Neurotrope Inc (OTCMKTS:NTRP) took a real hit earlier this month on the back of a private placement that saw it issue shares at a deep discount to market, and the company has failed to recover any substantial portion of the lost market cap...

In contrast to a number of our competitors, here at Insider Financial we’ve championed Anavex Life Sciences Corp (NASDAQ:AVXL) on a number of occasions in the recent past. The company is developing an Alzheimer’s therapy with a...

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter

Sign Up Now For Our FREE Small Cap Newsletter